Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations (original) (raw)
2004, Journal of Viral Hepatitis
Chronic hepatitis B and C represent a leading cause of morbidity and mortality among human immunodeficiency virus (HIV)-infected patients worldwide. New treatment options against both hepatitis B (HBV) and C (HCV) viruses have prompted us to update previous recommendations for the management of coinfected individuals. Fifteen topics (nine related to HCV, five to HBV and one to both viruses) were selected for this purpose. A panel of Spanish experts in the field was invited to review these areas and propose specific recommendations, which were scored according to the Infectious Disease Society of America (IDSA) grading system. These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV-infected patients.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Recent advances in management of the HIV/HCV coinfected patient
Future Virology, 2015
Chronic hepatitis C virus (HCV) is a global epidemic, affecting approximately 150 million individuals throughout the world. The implications of HCV infection have been magnified in those who are infected with both HCV and the HIV as liver disease progression, liver failure and liver-related death are increased, particularly in those without well-controlled HIV disease. The development of direct-acting antiviral agents for HCV that allow shorter treatment periods with increased efficacy and decreased adverse events have greatly changed the outlook for HCVinfected individuals. With these advancements, growing treatment options for the coinfected population have also come. This review will address pharmacotherapy issues in the HIV/HCV coinfected population. Keywords direct-acting antiviral; HCV; HIV; null responder; relapse; sustained virologic response Hepatitis C continues to be a major health issue in the USA and around the world. Current estimates are that 5.2 million individuals are living in the USA with HCV infection [1]. The WHO estimates that approximately 150 million individuals have chronic HCV infection and the yearly death-toll from HCV-related diseases is >350,000 [2]. The majority of individuals (∼77%) who become infected with acute HCV go on to develop chronic hepatitis [3]. Left untreated chronic HCV infection can lead to hepatic fibrosis and ultimately cirrhosis and liver cancer [3]. About 25% of the individuals infected with HIV in the USA are also infected with HCV, with the rate approaching 100% among injection-drug users with HIV [4]. Coinfection with HIV and HCV can result in a threefold greater rate of fibrosis progression as compared with those individuals with HCV monoinfection [5], especially among those with profound immune deficiency defined as low CD4 counts with or without AIDS and high levels of HIV RNA. Development of cirrhosis and end-stage liver disease can occur in six-ten years among coinfected patients whereas the natural history in those with HCV monoinfection ranges from 20-30 years [6]. This data substantiates the current recommendations for HCV screening among HIV-infected individuals [7]. In addition, it also underscores the importance of treating HIV infection successfully, and then proceeding to HCV treatment as soon as possible to control liver-disease progression. Treatment for chronic HCV has made great strides over the years with particularly important developments occurring since 2011. Initially interferon monotherapy was utilized with poorresponse rates, sustained virologic response (SVR) rates of 6% with 24 weeks of therapy, which increased with the combined use of ribavirin (RBV) [8,9]. In 2001 and 2002, pegylated-interferon (PEG-IFN) α-2b and α-2a were approved by the US FDA, respectively. When used in combination with RBV, PEG-IFN increased the therapeutic success and Bednasz et al.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.